Coordinatore | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
Nazionalità Coordinatore | Italy [IT] |
Totale costo | 10˙283˙796 € |
EC contributo | 5˙998˙890 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2013-INNOVATION-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
# | ||||
---|---|---|---|---|
1 |
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
IT (MILANO) | coordinator | 1˙315˙728.00 |
2 |
THE FOUNDATION FOR MEDICAL RESEARCHINFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV
Organization address
address: WEIZMANN STREET 6 contact info |
IL (Tel Aviv) | participant | 1˙007˙354.00 |
3 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 864˙150.00 |
4 |
MEDCOM GESELLSCHAFT FUER MEDIZINISCHE BILDVERARBEITUNG MBH
Organization address
address: RUNDETURMSTRASSE 12 contact info |
DE (DARMSTADT) | participant | 630˙500.00 |
5 |
SEROSCIENCE KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Organization address
address: LORANT UTCA 10 B EP FSZT 2 contact info |
HU (BUDAPEST) | participant | 478˙900.00 |
6 |
PRAXIS BIOPHARMA RESEARCH INSTITUTE SL
Organization address
address: CALLE HERMANOS LUMIERE 5 contact info |
ES (Vitoria-Gasteiz) | participant | 474˙301.00 |
7 |
CAMELOT BIOMEDICAL SYSTEMS SRL
Organization address
address: VIA GRETO DI CORNIGLIANO 6R contact info |
IT (GENOVA) | participant | 452˙840.00 |
8 |
ESAOTE SPA
Organization address
address: VIALE BIANCA MARIA 25 contact info |
IT (MILANO) | participant | 368˙750.00 |
9 |
NANOMOL TECHNOLOGIES SA
Organization address
address: LG EDIFICI EUREKA.CAMPUS UAB BELLATERRA contact info |
ES (CERDANYOLA DEL VALLES) | participant | 280˙574.00 |
10 |
CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL
Organization address
address: Via Giuseppe Mussi 1 contact info |
IT (MILANO) | participant | 125˙793.00 |
11 |
MAGFORCE AG
Organization address
address: MAX-PLANCK-STRASSE 3 contact info |
DE (BERLIN) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastomas, a rare cancer. Intraoperative Contrast-Enhanced US-imaging (CEUS) using lipidic MBs hold promises in increasing extent of resection of such tumors. Furthermore, MBs gained recently interest as a delivery system for drugs. We will develop a new generation of multimodal MBs, acting simultaneously as contrast agent for Magnetic Resonance Imaging (MRI), CEUS and intra-operative fluorescence for multimodal real-time image-guided resection of glioblastomas. We plan to transform MBs by replacing air with perfluorcarbon gas and/or attaching super-paramagnetic-iron-oxide nanoparticles for MRI visualization. We will also engineer MBs with RGD-motif to adhere selectively to pathological endothelial integrins and with near-infrared fluorophores for simultaneous US deep tissue imaging and direct microscopic tumour visualization to maximize resection. A software will be developed for integration of preoperative MRI, intraoperative US and microscopic imaging. We will focus on lipidic and polymeric MBs. Lipidic MBs are approved for clinical use; therefore, once modified, more easily translatable into clinical applications to reach a feasibility study on patients. In addition, we will improve multifunctional, polymer-based MBs. Multifunctional-stabilized-polymer-MBs are more stable and more versatile to be complexed with different molecules or nanoparticles as compared to lipidic Mbs and will be designed as a platform for delivering standard and/or experimental chemotherapeutic drugs to the tumour, acting as an innovative way for local targeting and delivering any kind of agent to a specific target, in a safe and controlled fashion. This would be a big step forward in the field of personalized medicine, moving standard MG image-guided treatment towards more effective, safer, molecular-based tailored interventions to specific patients.'
"Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application"
Read MoreEURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma
Read MoreDevelopment of Functionalised Cell Seeded Bioartificial Organ for Transplantation in Nerve Repair
Read More